Jennifer Kim
Stock Analyst at Cantor Fitzgerald
(1.53)
# 3,222
Out of 4,834 analysts
42
Total ratings
34.21%
Success rate
-4.93%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jennifer Kim
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PGEN Precigen | Reiterates: Overweight | n/a | $1.31 | - | 4 | May 15, 2025 | |
| BLTE Belite Bio | Reiterates: Overweight | n/a | $64.50 | - | 4 | Mar 18, 2025 | |
| INSM Insmed | Reiterates: Overweight | n/a | $66.10 | - | 8 | Feb 20, 2025 | |
| FBIO Fortress Biotech | Reiterates: Overweight | n/a | $1.70 | - | 4 | Jun 20, 2024 | |
| EYPT EyePoint Pharmaceuticals | Reiterates: Overweight | n/a | $5.55 | - | 6 | Jun 20, 2024 | |
| ALLK Allakos | Reiterates: Neutral | n/a | $0.33 | - | 4 | Jun 20, 2024 | |
| OCGN Ocugen | Maintains: Overweight | $2.5 → $2 | $0.64 | +210.37% | 2 | Aug 31, 2023 | |
| CKPT Checkpoint Therapeutics | Maintains: Overweight | $19 → $14 | $4.16 | +236.54% | 4 | Aug 15, 2023 | |
| LPCN Lipocine | Reiterates: Overweight | $33 | $3.36 | +882.14% | 2 | Jul 27, 2023 | |
| PRQR ProQR Therapeutics | Maintains: Overweight | $5 → $4.5 | $1.54 | +192.21% | 2 | May 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $220 → $100 | $1.99 | +4,925.13% | 2 | May 17, 2022 |
Precigen
May 15, 2025
Reiterates: Overweight
Price Target: n/a
Current: $1.31
Upside: -
Belite Bio
Mar 18, 2025
Reiterates: Overweight
Price Target: n/a
Current: $64.50
Upside: -
Insmed
Feb 20, 2025
Reiterates: Overweight
Price Target: n/a
Current: $66.10
Upside: -
Fortress Biotech
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.70
Upside: -
EyePoint Pharmaceuticals
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $5.55
Upside: -
Allakos
Jun 20, 2024
Reiterates: Neutral
Price Target: n/a
Current: $0.33
Upside: -
Ocugen
Aug 31, 2023
Maintains: Overweight
Price Target: $2.5 → $2
Current: $0.64
Upside: +210.37%
Checkpoint Therapeutics
Aug 15, 2023
Maintains: Overweight
Price Target: $19 → $14
Current: $4.16
Upside: +236.54%
Lipocine
Jul 27, 2023
Reiterates: Overweight
Price Target: $33
Current: $3.36
Upside: +882.14%
ProQR Therapeutics
May 17, 2023
Maintains: Overweight
Price Target: $5 → $4.5
Current: $1.54
Upside: +192.21%
May 17, 2022
Maintains: Overweight
Price Target: $220 → $100
Current: $1.99
Upside: +4,925.13%